We are live on ! Find out more
ENSC icon

Ensysce Biosciences
ENSC

16 hedge funds and large institutions have $833K invested in Ensysce Biosciences in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 16 → 16 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

76% less capital invested

Capital invested by funds: $3.41M → $833K (-$2.57M)

Holders
16
Holders Change
–
Holders Change %
0%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
–
Closed
5
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$146K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$88K
2
Cerity Partners
Cerity Partners
New York
+$68.5K
3
Northern Trust
Northern Trust
Illinois
+$22.8K
4
VF
Virtu Financial
New York
+$19.6K
5
UBS Group
UBS Group
Switzerland
+$14.7K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$309K
2
AFM
Anson Funds Management
Texas
-$131K
3
Citigroup
Citigroup
New York
-$62K
4
PIA
Powell Investment Advisors
Florida
-$61K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$13K
Name Holding Trade Value Shares
Change 		Change in
Stake
HVCM
1
HG Vora Capital Management
New York
$529K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$68K +$88K +54 +159%
BlackRock
3
BlackRock
New York
$50K – – –
Stifel Financial
4
Stifel Financial
Missouri
$47K – – –
Cerity Partners
5
Cerity Partners
New York
$32K +$68.5K +42 New
Geode Capital Management
6
Geode Capital Management
Massachusetts
$28K +$1.63K +1 +3%
MGIA
7
Moneta Group Investment Advisors
Missouri
$22K +$1.63K +1 New
UBS Group
8
UBS Group
Switzerland
$11K +$14.7K +9 +180%
Northern Trust
9
Northern Trust
Illinois
$11K +$22.8K +14 New
VF
10
Virtu Financial
New York
$9K +$19.6K +12 New
State Street
11
State Street
Massachusetts
$8K – – –
TSS
12
Two Sigma Securities
New York
$7K +$3.26K +2 +29%
Jane Street
13
Jane Street
New York
$4K +$9.78K +6 New
TRCT
14
Tower Research Capital (TRC)
New York
$3K +$4.89K +3 +300%
SG
15
StoneX Group
New York
$2.75K +$1.63K +1 +33%
WAM
16
Wolverine Asset Management
Illinois
$1K – – –
Renaissance Technologies
17
Renaissance Technologies
New York
– -$309K -99 Closed
AFM
18
Anson Funds Management
Texas
– -$131K -42 Closed
Citigroup
19
Citigroup
New York
– -$62K -20 Closed
PIA
20
Powell Investment Advisors
Florida
– -$61K -19 Closed
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
– -$13K -4 Closed

ENSC Hedge Fund Activity: Q3 2022 in Review

16 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q3 2022, worth a combined $833K — down 76% from $3.41M a quarter earlier.

Fund positioning in ENSC was balanced in Q3 2022: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, adding an estimated $88K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $309K sold.

  • 16 institutional investors held Ensysce Biosciences (ENSC) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $833K of Ensysce Biosciences stock for Q3 2022, down 76% quarter-over-quarter.
  • 5 funds opened new Ensysce Biosciences positions in Q3 2022 and 5 closed out, a net change of 0 holders.
  • The largest Ensysce Biosciences buyer in Q3 2022 was Vanguard Group, an estimated $88K added.
  • The largest Ensysce Biosciences seller in Q3 2022 was Renaissance Technologies, an estimated $309K sold.

Based on aggregated 13F filings for Q3 2022.